Biotechnology a la francaise
Biotechnologies are actively developing in France
Medicine and Pharmacy News from RemediumIn France in Lille on September 23-25, 2009.
The EuroBio conference will be held. Like other conferences such as Bio USA and Bio Japan, their European version, EuroBio, is a key event for the international community dealing with the problems of natural sciences.
The previous EuroBio conference, held in Paris in 2008, was attended by more than 20 countries, 5,000 participants, 120 international speakers and 500 firms and groups of companies.
Addressing the problems arising at the junction of scientific research and industrial production, and focusing on all key topics related to various branches of biotechnology application (healthcare, technological processes and agriculture), EuroBio allows you to conduct an annual analysis of the progress of research and development, as well as the economic situation in one of the most important sectors of industry of great importance for the future of humanity and its environment.
Healthcare is a field of application of biotechnologies, standing in the first place. France ranks third among European countries in this sector, after the United Kingdom and Germany. French companies engaged in biotechnology (such as Bio-Alliance, Nicox, ExonHit, Hybrigenics, etc.) are very active and are at the forefront in the field of scientific research.
Some of them may find support from large pharmaceutical groups, which are often the only companies capable of investing heavily in research and development. Foreign pioneer companies in the field of biotechnology, such as Amgen, Genentech or Genzyme (all operating in France), have become "biopharmacological" companies engaged in the sale of essential medicines.
The strategic importance of these biotech companies cannot be understated, given that most of the future drugs will be created on the basis of biotechnologies.
The dynamism of France is also based on the advanced research carried out in this country in the field of health, which is confirmed by the award last year of the 2008 Nobel Prize in Medicine to Professors Françoise Barré-Sinoussi and Luc Montagnier at the Pasteur Institute in Paris for their work leading to the discovery of the retrovirus that causes human immunodeficiency syndrome (AIDS). At the University of Génopôle d'evry, where work on biotechnology is carried out, Jean Weissenbach, director of the company Génoscope, developed the first mapping of the human genome, with high resolution.
Such dynamism is now supported by the provision of a tax credit for scientific research, which is a very stimulating factor for Europe. It is in this context that the newly created Japanese company CellSeed, engaged in biotechnology and, in particular, cell therapy, decided to settle in Lyon, due to the high quality of clinical testing platforms in France, transparency in the field of regulation, the high ethics of the French culture in dealing with patients and the presence of expert specialists in this region.
According to David Appia, President and CEO of the Investment Agency for the French Economy (the Invest in France Agency), healthcare is a national priority in France. The development of medical products of the future will require the use of biotechnologies to an increasing extent.
France, being at the forefront of European countries in the field of biotechnology, has all the advantages to convince companies engaged in biotechnology, which are mostly small and medium-sized businesses, to make a choice towards their location on its territory. The EuroBio conference, which will be held in Lille in September this year, will be the place of their general meeting.
Portal "Eternal youth" http://vechnayamolodost.ru17.09.2009